Oligodendroglioma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) HC (1) | IDH1 p.R132C | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132G | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132H | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132L | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132S | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172K | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172M | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172G | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172S | Oligodendroglioma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172W | Oligodendroglioma | Vorasidenib |